<DOC>
	<DOCNO>NCT01126970</DOCNO>
	<brief_summary>To evaluate weight loss effect safety 400 mg velneperit 120 mg orlistat administer individually combine three time per day 24 week reduce calorie diet ( RCD ) also evaluate steady-state trough concentration velneperit ( S-2367 ) , velneperit ( S-2367 ) tert-butyl OH , velneperit ( S-2367 ) tert-butyl OH-O glucuronide follow 400 mg velneperit ( S-2367 ) three time per day 120 mg orlistat , either combine separate .</brief_summary>
	<brief_title>Double-Blind , Multi-Center , Randomized Study Assess Efficacy Safety Velneperit ( S-2367 ) Orlistat Administered Individually Combined With Reduced Calorie Diet ( RCD ) Obese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Orlistat</mesh_term>
	<criteria>Males females 18 65 year age time informed consent Body mass index ( BMI ) 30.0 45.0 kg/m2 inclusive . BMI study inclusion must obtain Interactive Voice Response System/Web Response System ( IVRS/WRS ) . ( Visit 1 body weight height obtain prior singleblind period use IVRS/WRS calculation . ) Weight fluctuate 3 % 90 day prior Visit 1 Nonsmoker use tobacco nicotine product least 1 year prior Visit 1 Normotensive acceptable level hypertension , define systolic &lt; 160 diastolic &lt; 95 mmHg No clinically significant laboratory abnormality Negative urine drug screen drug abuse No clinically significant finding medical history , physical examination , electrocardiogram ( ECG ) know history clinically significant ECG abnormality Negative serum pregnancy test woman childbearing potential ( Females must least one year postpartum . ) Males either remain abstinent , sterile agree use approve method contraception ( male include use condom spermicide ) Visit 1 12 week follow last dose , addition female partner use effective form contraception note All female subject must nonpregnant ( confirm negative serum pregnancy test ) , plan become pregnant study , must least one year postpartum , nonlactating , postmenopausal , ( define cessation regular menstrual period least one year confirm folliclestimulating hormone test ) , surgically sterile hysterectomy and/or bilateral oophorectomy tubal ligation . Females childbearing potential must agree use acceptable form birth control include oral , implantable transdermal contraceptive ; use one follow doublebarrier method : intrauterine device spermicide , diaphragm spermicide , cervical cap spermicide , female condom spermicide , male condom spermicide male sexual partner Able comply require study procedure schedule Able speak read English Signed date informed consent form prior studyrelated procedure Obesity know endocrine genetic origin ( eg , hypothyroidism , Cushing 's syndrome diagnose polycystic ovarian syndrome ) meet one follow condition : Menstrual irregularity due oligo anovulation Evidence hyperandrogenism , whether clinical ( hirsutism , acne , male pattern bald ) biochemical ( high serum androgen concentration ) Exclusion cause hyperandrogenism menstrual irregularity , congenital adrenal hyperplasia , androgensecreting tumor , hyperprolactinemia ] History malignancy within previous 5 year exception nonmelanoma skin cancer surgically cure cervical cancer Human immunodeficiency virus ( HIV ) identify history previous HIV test Any serious medical condition , opinion Investigator , would limit subject 's ability complete and/or participate clinical study include clinically significant finding medical history , physical examination , 12lead ECG , vital sign Known history evidence psychiatric disorder opinion investigator would preclude subject participate trial . Stable controlled anxiety depression permit . Treatment antidepressant anxiolytic drug permit accordance Appendix 4 . Subjects score 11 high depression portion Hospital Anxiety Depression Scale exclude . Subjects pancreatitis chronic pancreatic inflammation History Type 1 Type 2 diabetes mellitus define HbA1c &gt; 6.5 % blood glucose value &gt; 126 mg/dl treat Type 2 diabetes mellitus Any weight gain singleblind leadin period ( Visit 1 Visit 3 ) History surgical device ( eg , gastric bypass ) intervention obesity surgery , stomach band surgery , surgical procedure ( ) attempt promote/aid weight loss . Note : Liposuction allow do 90 day prior screen History alcoholism drug addiction/substance abuse within 1 year Visit 1 . Note : No alcohol consumption permit within 48 hour prior blood collection analysis lipid profile . Abnormal thyroid stimulate hormone level screen Subjects hypothyroidism Subjects genetic hematologic disease trait without manifestation disease . Use chronic medications/products within 90 day prior Visit 1 study know cause weight gain . Investigators discuss Sponsor 's Medical Monitor concomitant medication uncertain . Use systemic corticosteroid Depo ProveraÂ® History fenfluramine dexfenfluramine ( FenPhen ) administration ( except prior document echocardiogram showing valvular abnormality . ) History participation weight loss program within 90 day prior Visit 1 Participation weight loss medication/product study receipt weight loss medication/product occur within 90 day prior Visit 1 Use prescription nonprescription counter medication/product herbal/phytotherapeutic/plantderived medications/products weight loss , appetite suppression , weight control treat obesity ( include investigational product ) within 90 day prior Visit 1 study Subjects cholestasis chronic malabsorption Donation blood blood product 90 day prior Visit 1 study Exposure investigative medication within past 30 day 5 halflives , whichever longer concurrent participation clinical trial Previous velneperit ( S2367 ) neuropeptide Y ( NPY ) Y5 agonist antagonist use Any acute chronic condition , opinion Investigator , would limit subject 's ability complete and/or participate clinical study Positive Hepatitis B C serology</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>reduce calorie diet</keyword>
	<keyword>orlistat</keyword>
	<keyword>velneperit</keyword>
</DOC>